ABSTRACr A complex between soluble dextran and human hemoglobin has been synthesized by two different methods. In the atkylation method, hemoglobin was allowed to react with bromoacetyl groups incorporated into the dextran; the yield of the complex was about 80% in terms of the hemoglobin used. In the dialdehyde method, hemoglobin was allowed to react with dialdehyde groups on the dextran generated by periodate oxidation; the yield of the complex was about 60%. Both soluble dextran-hemoglobin complexes could bind and release oxygen reversibly, but the oxygen-binding curves were shifted to the left relative to that of free hemoglobin. In the rabbit, the complex obtained by the alkylation method was excreted by the kidneys and cleared from the circulation much more slowly than free hemoglobin.
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The possibility of application of hemoglobin solutions as a blood substitute, serving at once the dual functions of plasma expansion and oxygen delivery, has long been considered (1) (2) (3) , and is enhanced by the recent discovery by Rabiner et al. (4) that the removal of erythrocyte stroma effectively detoxifies such solutions. In view of the advantages that stroma-free hemoglobin can be sterilized by filtration, easily stored, and used in transfusions without blood-group typing, its physiological properties have been widely examined, advancing as far as the stage of clinical trials (5) . However, due to its relatively small size, hemoglobin infused into the circulation is rapidly eliminated through the kidneys and by other metabolic routes (4, 6) . This severely limits its utility and may be of particular concern with respect to preexistent renal diseases (7) . Accordingly, it would be important to develop usable procedures that can increase the effective size of the hemoglobin molecule and slow down its disappearance from the circulation. Previously, Payne (8) had crosslinked hemoglobin with glutaraldehyde, and Mok et al. (9) with diimidate, to form polymers of hemoglobin, but the spread in molecular weights of these polymers was wide, and it is not known if they retain the capacity to bind and release oxygen reversibly. Chua and Bushuk (10) and Colosimo et al. (11) had coupled hemoglobin to insoluble agarose and dextran matrices, but the insoluble matrices used are not usable for transfusions. The purpose of this study is to overcome these difficulties by developing methods for covalently coupling hemoglobin to soluble dextran to form a functional dextranhemoglobin complex. Since dextrans are valuable plasma expanders, obtainable in well-defined ranges of molecular weights, and easily derivatized with various chemical groupings, this approach opens up the possibility of the systematic design of a dextran-hemoglobin complex that may, with respect to both size and chemical configuration, optimally serve as a blood substitute.
MATERIALS AND METHODS
Synthesis of Dextran-Hemoglobin by the Alkylation Method. In this method, the dextran was first derivatized to contain a bromoacetyl function. In a typical preparation, 0.3 g of cyanogen bromide (Eastman Co.) was dissolved in 3 ml of acetonitrile and added to 100 ml of 2% dextran (molecular weight 200,000-275,000, from BDH Biochemicals). The pH was maintained at 10.8 for 5 min by the addition of 1 M NaOH; it was then lowered to about 2.0-2.5 with concentrated HC1, and 2 ml of diaminoethane was added along with additional HC1 in order to prevent the pH from exceeding 9.5; the final pH was adjusted to 9.5. After standing overnight at 40, the mixture was thoroughly dialyzed against distilled water using a Bio-Fiber beaker (Bio-Rad Laboratories) and lyophilized. The aminoethylamino-dextran so obtained was dissolved in 50 ml of 0.1 M phosphate (sodium salt), pH 7.0, and 2 ml of bromoacetylbromide (Eastman Co.) was added through a pasteur pipette with a finely drawn capillary tip and accompanied by vigorous stirring over a period of 2 hr; throughout, the pH was maintained at 7.0 with the addition of 1 M NaOH. Afterwards, the mixture was dialyzed thoroughly against distilled water and lyophilized to yield about 1. 10 ml of the reaction mixture was placed on a 7-liter Sephadex G-200 column equilibrated with 0.05 M phosphate (sodium salt), pH 7.0, and chromatographed at a flow rate of 2.5 ml/min. The dextran-hemoglobin formed emerged from the column at about 1400 ml; from separate chromatograms, free hemoglobin was known to emerge at about 3100-3300 ml.
and dextran-hemoglobin was determined according to Benesch et al. (14) .
Renal Excretion of Hemoglobin and Dextran-Hemoglobin. Rabbits (male oxy-inulin (New England Nuclear, 221 mCi/g), was infused into each animal through the marginal ear vein at 1.1 ml/min. After the solution had been infused, infusion was continued at the same rate with the buffer to maintain urinary output. At intervals, the content of the bladder was washed out with three 5-ml portions of 0.9% saline with the use of a Foley no. 8 catheter (3 ml) and, after centrifugation at 3000 X g for 10 min to remove any sedimentable material, the dissolved hemoglobin or dextran-hemoglobin in the combined washes was determined on the basis of absorbance at 576 nm. The [3H]inulin content in the combined washes was measured by scintillation counting with correction for quenching by hemoglobin; an external radiation standard in the Nuclear Chicago Mark II counter was used to determine quenching. Plasma concentration of hemoglobin or dextran-hemoglobin was determined at various times by withdrawing blood samples from the carotid artery and making absorbance measurements on the samples at 576 nm after sedimenting the erythrocytes.
RESULTS
When dextran (molecular weight, 200,000-275,000) was coupled to hemoglobin by either the alkylation or the dialdehyde method, the dextran-hemoglobin complex formed could be separated from uncoupled hemoglobin by means of gel filtration on Sephadex G-200 (Fig. 1) . The yield of dextran-hemoglobin in terms of the hemoglobin used was over 80% in the alkylation method and about 60% in the dialdehyde method. This corresponded to about 2.7 mol of hemoglobin (molecular weight, 64,000) coupled to each mole of dextran (molecular weight, about 240,000) in the alkylation method, and 2.0 mol of hemoglobin in the dialdehyde method. In order to obtain a high yield of dextran-hemoglobin by the alkylation method, the dialysis steps in the procedure had to be performed thor- oughly. The addition of bromoacetylbromide to the aminoethylamino-dextran also had to be extremely slow, most likely because a fast addition would reduce the acylation reaction relative to the hydrolysis of bromoacetylbromide.
Neither coupling method caused any gross spectral damage to the hemoglobin (Fig. 2) , but the dextran-hemoglobins obtained by the two methods differed from each other as well as from free hemoglobin with respect to oxygen binding. The oxygen-binding curve of dextran-hemoglobin (alkylation method) was shifted to the left compared to free hemoglobin, resulting in a 2.5-fold greater affinity for oxygen as measured by the half-saturation oxygen tension. The sigmoidicity of the curve was also reduced relative to that of free hemoglobin. The oxygen-binding curve of dextran-hemoglobin (dialdehyde method) was shifted even more to the left than that of dex- Urinary excretion and plasma level of infused hemoglobin (Hb) and dextran-hemoglobin (Dx-Hb) prepared by the alkylation method. Prior to infusion, both hemoglobin and dextran-hemoglobin were incubated with 128 mM mercaptoethanol for 16 hr at 4°in order to remove unreacted bromine on the dextran and then dialyzed against kidney dialyzing buffer. Sample was infused into rabbit at the rate of 1.1 ml/min; after infusion of the sample was completed, infusion with the kidney dialyzing buffer alone was continued at the same rate. The sample consisted of (a) 50 ml of 1% Hb, (b) 30 ml of 1% Hb, (6) 50 ml of Dx-Hb containing 1% equivalent of hemoglobin, and (d) 30 ml of Dx-Hb containing 1% equivalent of hemoglobin. Symbols: excretion of inulin (X), excretion of hemoglobin (-), and plasma level of hemoglobin (0). The excretion and the plasma level of hemoglobin were expressed in terms of molarity with respect to the heme moiety.
tran-hemoglobin (alkylation method). However, both dextran-hemoglobins functioning in phosphate buffer bound oxygen more tightly than free hemoglobin also functioning in phosphate buffer, but more loosely than free hemoglobin functioning in the absence of phosphate (Fig. 3) .
The increased size of dextran-hemoglobin was already evident from its separation from uncoupled hemoglobin on Sephadex G-200. This was further confirmed by ultracentrifugation. The sedimentation coefficient for dextran-hemoglobin (alkylation method) at the midpoint of its concentration boundary was 7.7 S, in contrast to the value of 3.9 S for free hemoglobin.
When infused into rabbits, dextran-hemoglobin (alkylation method) was excreted through the kidneys and removed from circulation at a greatly reduced rate compared to free hemoglobin even though renal function in the animals infused with dextran-hemoglobin, as indicated by inulin excretion, was unimpaired (Fig. 4) . Furthermore, since it was repeatedly observed with different animals and at different dosages of infusion, this dissimilar physiological behavior of dextranhemoglobin and free hemoglobin was clearly attributable to the large difference in their molecular size rather than to some chance variation in, for example, the blood haptoglobin level of the experimental animals.
DISCUSSION
The present study describes two methods for covalently coupling hemoglobin to soluble dextran. There are many methods for coupling proteins to insoluble polysaccharide matrices, but some of these are poorly adapted toward the coupling of hemoglobin to soluble polysaccharides. For example, although the cyanogen bromide method (15) can directly couple proteins to insoluble polysaccharide matrices, the cyanogen bromide was difficult to remove exhaustively from soluble dextran, and even traces of the reagent caused spectral damage to the heme; accordingly, in this study cyanogen bromide was used in the alkylation method, but not directly on hemoglobin. Thus, the alkylation and dialdehyde methods have been selected for development in this study on account of both their high yields and lack of spectral damage to the heme. The chemical steps involved in these two methods, on the basis of the known reactions of the reagents used, are: (Fig. 3) . In any event, this property of the dextran-hemoglobin complex clearly depended on its method of synthesis. Other methods of coupling therefore deserve to be continually developed and investigated in order to obtain dextran-hemoglobin complexes with different oxygen-binding behavior as well as other important functional characteristics.
The dextran-hemoglobin prepared by the alkylation method possesses three attractive characteristics that contribute to its potential usefulness as a blood substitute. First, it can bind and release oxygen reversibly. Second, it is cleared through the kidneys and removed from the circulation much more slowly than free hemoglobin, thus at once preventing massive hemoglobinuria and increasing the functional life span of the hemoglobin molecule. Third, the high yield with which dextran-hemoglobin can be prepared effectively minimizes the need for its cumbersome fractionation from residual free hemoglobin prior to use in transfusions.
The potential usefulness of the dextran-hemoglobin complex may yet require improvement in two basic aspects. First, the complex synthesized by the alkylation method, although less abnormal than that synthesized by the dialdehyde method, has an oxygen-binding curve that is shifted to the left relative to that of free hemoglobin. It is commonly assumed that an oxygenbinding curve for hemoglobin that has been shifted to the right, bringing a loosened binding of oxygen, might be an essential requirement for efficient oxygen delivery in divo, and that 2,3-diphosphoglycerate serves as the effector for the shift to the right. This assumption receives support from the observed regulation of 2,3-diphosphoglycerate concentration inside erythrocytes under various physiological conditions (17) , but Harris (18) has suggested that some shifting of the oxygenbinding curve might be of little importance in determining the efficiency of oxygen delivery compared to the state of the microcirculation. Thus, the relative flow properties of hemoglobin and dextran-hemoglobin might be at least as important as their relative oxygen affinities in this regard. In any event, Fig. 3 shows that dextran-hemoglobin functioning in the presence of phosphate binds oxygen more tightly than free hemoglobin also functioning in the presence of phosphate, but more loosely than free hemoglobin functioning in the absence of phosphate. Accordingly, the synthesis of a dextran-hemoglobin complex with an oxygen-binding curve shifted to the right relative to free hemoglobin might be sought through the covalent incorporation of phosphates or other anions into the complex, e.g., by means of reaction between the hemoglobin and pyridoxal phosphate (19) or replacement of the dextran by dextran phosphate. Second, since larger dextrans are more antigenic (20) , the use of smaller dextrans for building the dextranhemoglobin complex might reduce its antigenicity. On the other hand, too small a dextran may not bring a sufficient increase in the effective size of the hemoglobin. Therefore, the optimal size of dextran still remains to be determined.
In conclusion, the soluble dextran-hemoglobin complex offers the important advantages over free hemoglobin of prevention of massive hemoglobinuria and a longer functional life span. Although further inquiry may reveal unforeseen disadvantages of such a complex, it is useful to note that there are many conceivable ways by which dextran may be chemically modified and covalently coupled to hemoglobin, in addition to the possibility of replacing dextran itself by other polysaccharides, such as hydroxyethyl starch. Consequently, the construction and behavior of the soluble dextran-hemoglobin complex is open to a wide range of variations. These variations should provide a basis for maximizing the advantages of the complex as a blood substitute and minimizing its disadvantages by means of systematic molecular design and synthesis.
